JPRN-UMIN000021954招募中未知
Examination of the efficacy of dapagliflozin in patients with type 2 diabetes - Efficacy of dapagliflozin
Tonami general hospital Department of diabetes mellitus and endocrinology0 个研究点目标入组 200 人开始时间: 2016年5月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with hypersensitivity to an ingredient of dapagliflozin 2.Diabetic ketoacidosis 3.Past history of coma or severe hypoglycemia 4.Severe infection or serious trauma 5.Severe liver injury, renal failure, cardiac disease, proliferative retinopathy 6.Past history of cerebral infarction 7.Past history of malignant tumor 8.Women with during pregnancy, nursing, or pregnant likelihood 9.Inadequate patients judged by doctor
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003897-41-DKAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-BGAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.EUCTR2016-003897-41-SEAstraZeneca AB4,500
已完成
3 期
DAPA-HFChronic Heart Failure With Reduced Ejection Fraction (HFrEF)JPRN-jRCT2080223469AstraZeneca KK330